larly true for 2′,3′-dideoxynucleosides and acyclic nucleoside phosphonate analogues, the prototype of which is 9-(2-phosphonylmethoxyethyl)adenine (PMEA) . PMEA was therefore tested in lambs inoculated with visna virus in order to study its inhibitory effect in vivo (Thormar et al., 1995) . PMEA was injected subcutaneously (s.c.) 1 h before intracerebral (i.c.) inoculation and thereafter three times weekly for a period of 6 weeks. The results showed a very pronounced inhibitory effect of PMEA on virus replication and the evolution of brain lesions in visna virus-infected lambs. Since the study showed that the effect of PMEA on early visna virus infection was comparable to its effect in other in vivo retrovirus models (Naesens et al., 1994) , it was concluded that visna virus infection in sheep can be used as an animal model for testing the effects of antiretroviral drugs on brain infections caused by lentiviruses, such as HIV-1. Antiviral Chemistry & Chemotherapy 9: [245] [246] [247] [248] [249] [250] [251] [252] 
Treatment of visna virus infection in lambs with the acyclic nucleoside phosphonate analogue 9-(2-phosphonylmethoxyethyl)adenine (PMEA) Introduction
Because of the encouraging results obtained in the former experiment it was decided to study the therapeutic efficacy of PMEA in an experiment extending over a longer period of time and with treatment starting 1 month after inoculation, when visna virus infection has generally been established and CNS lesions have appeared (Pétursson et al., 1976) . In contrast to the pronounced prophylactic effect of PMEA demonstrated in the former study, the drug showed only a minor therapeutic effect in established visna virus infection in lambs.
Materials and Methods

Virus and cell cultures
Visna virus strain KV1772, which is a biological clone with increased neurovirulence (Andrésson et al., 1993) , was used for inoculation of lambs and antibody assays. Sheep choroid plexus cell (SCPC) monolayer cultures were used for preparation of virus stocks, virus titrations and neutralization tests. The cultures were grown in Eagle's MEM (Gibco) with 20% heat-inactivated lamb serum (Gibco). The maintenance medium was MEM with 2% lamb serum. Virus titres were determined by inoculation of 10fold dilutions into SCPC monolayers in 96-well microtitre tissue culture (TC) plates (Nunc). Virus-induced cytopathic effect (CPE) was examined at 14 days after virus inoculation, and the virus titres were calculated by the method of Reed & Muench (1938) .
Inoculation of lambs
Fifteen 4-6-week-old Icelandic lambs, with an average weight of 6.3 kg, were inoculated i.c. with 10 6.3 CCID 50 (50% cell culture infectious dose) of biological clone KV1772 of visna virus. They were fed a milk formula feed supplemented with minerals and freshly mown grass for about 6 weeks and thereafter hay and water ad libitum. The lambs were weighed at the beginning of the experiment and then once a week.
Administration of drug
PMEA was kindly supplied by N Bischofberger (Gilead Sciences, Foster City, Calif., USA). It was dissolved in PBS pH 7.2, at a concentration of 50 mg/ml. Administration of the drug was begun 1 month after virus inoculation. Seven lambs were injected s.c. with 10 mg/kg PMEA three times a week. A control group of eight lambs was not treated. The two groups were housed separately. At 2-4 months after the start of treatment, three lambs in each group were euthanized. For the remaining four lambs of the treated group, administration of the drug was continued for a total of 8 months. Since the administration of three weekly doses of 10 mg/kg PMEA seemed to have only a minor therapeutic effect but was well tolerated by the lambs, the dose was increased to 25 mg/kg PMEA three times a week for the last 2 months of the treatment. The four treated lambs and the five untreated control lambs were euthanized 9 months after inoculation with virus.
Isolation of virus from blood and cerebrospinal fluid (CSF)
Blood was drawn from the jugular vein at weekly intervals for 8 weeks, then every 2 weeks for 10 weeks and every 4 weeks for 16 weeks. The lambs were bled biweekly during the last month of the experiment. Peripheral blood mononuclear cells (PBMC) were separated from heparinized blood by sedimentation on Histopaque-1077 (Sigma). The PBMC were tested for virus by inoculation of 5-10×10 6 cells onto SCPC monolayers in 50 ml tissue culture flasks (Nunc). The number of virus-infected PBMC was estimated by inoculation of dilutions containing 10 5 and 10 6 cells onto SCPC monolayers in 24-well TC plates. The cultures were examined for visna virus CPE weekly for 4 weeks. Passages were made after 3 weeks and examined for CPE for 4 weeks. CSF was collected by lumbar puncture three times during the experiment, at 4 and 9 weeks after inoculation and at euthanasia. After counting of the cells in the CSF, they were separated by centrifugation and tested for virus as described for PBMC. The CSF supernatants were tested for virus in the same way.
Isolation of virus from organs
At euthanasia, tissue samples were collected from four separate areas of the right half of the brain, cerebral hemisphere, cerebellum, brainstem and choroid plexus of the lateral ventricles, from right and left lung, spleen and cervical, mediastinal and mesenterial lymph nodes. Explant cultures were made from about 100 mg of tissue and kept in growth medium until widespread cellular outgrowth had formed. The cultures were then changed to maintenance medium and examined for visna virus CPE weekly for 5 weeks. Passages were made every 2-3 weeks and examined for CPE for 4 weeks. Samples from all the tissues used for explantation, except for the choroid plexus, were frozen at -80°C. They were later thawed and homogenized in glass tissue grinders in ice-cold maintenance medium at 200 mg/ml. The homogenates were centrifuged at 3500 r.p.m. for 10 min at 0°C in a Sorvall RT 6000D centrifuge and 2 ml of supernatant inoculated into SCPC monolayers in 50 ml TC flasks. The monolayers were examined for CPE and culture fluids passaged as described for explant cultures.
Assays for PMEA sensitivity
Visna virus isolates from PMEA-treated lambs were titrated and their sensitivity to PMEA was assayed in monolayers of SCPC in 96-well TC plates, as previously described (Thormar et al., 1993) . Briefly, 10 µl of each virus isolate were inoculated into wells at a m.o.i. of 0.05 CCID 50 . Series of fivefold dilutions of PMEA in maintenance medium were added to each isolate in duplicate wells and the plates incubated at 37°C for 6 days. The monolayers were then fixed and stained and the CPE evaluated by microscopic examination. The inhibitory effect of PMEA is expressed as EC 50 (50% effective concentration), the concentration which causes a 50% reduction in visna virus-induced multinucleated syncytia. Syncytium formation correlates directly with virus replication (Thormar et al., 1993) . The original virus used for i.c. inoculation was included in each test.
Serum antibody assays
Serum was collected at 2 or 4 week intervals during the experiment. Neutralizing serum antibodies were tested as described earlier (Thormar et al., 1983) using 100 CCID 50 of virus mixed with twofold serum dilutions in maintenance medium. The mixtures were incubated at room temperature for about 20 h and then inoculated into duplicate wells of SCPC monolayers in 96-well TC plates. CPE was read at 14 days and the neutralizing titres are expressed as the highest serum dilution which completely neutralizes the virus.
ELISA was performed as described earlier (Torsteinsdóttir et al., 1992) . Microtitre plates (Dynatech-Immunlon) were coated with concentrated visna virus antigen and threefold dilutions of sera were tested starting with a dilution of 1 : 200. Rabbit anti-goat IgG conjugated to horseradish peroxidase (Sigma) was used and bound antibody was detected with H 2 O 2 /o-phenylenediamine dihydrochloride. The absorbance was read at 492 nm in a Titertek Multiskan Plus (Flow Laboratories).
Analysis of PMEA in sera and CSF
Blood was drawn from two healthy uninoculated sheep before and at 1, 2, 3 and 4 h after s.c. administration of PMEA at a dose of 25 mg per kg body weight. CSF was collected by lumbar puncture at 3 and 4 h after PMEA administration. PMEA concentrations in samples of serum and CSF were determined by reverse-phase HPLC analysis as described (Naesens et al., 1992) .
Histology
Specimens were collected at euthanasia. The left half of the brain was fixed in 4% formaldehyde in PBS. Nine blocks were cut at standard levels, embedded in paraffin and sections stained with haematoxylin and eosin. The brain lesions were graded on a scale of 0 to 6, modified from Pétursson et al. (1976) , where 6 represents the most severe lesions. Samples were also taken from heart, lungs, liver, kidney, spleen and cervical, mediastinal and mesenterial lymph nodes and prepared for histopathological examination.
Clinical evaluation
The lambs were examined regularly for signs of drug toxicity and clinical manifestations of visna virus or other infections. Blood samples were tested for haematological and biochemical parameters (differential cell counts, haemoglobin, liver enzymes, urea and creatinine) early in the study and at intervals until euthanasia.
Statistical analysis
A two-tailed Student's t-test was used. A value of P<0.05 was considered statistically significant.
Results
Isolation of visna virus from blood and CSF of PMEA-treated and control lambs
During the period from 2 to 6 weeks after inoculation, virus was isolated from the PBMC of 60-100% of blood samples from lambs in both groups, with a mean of 82.5 and 82.9%, respectively (Table 1, Fig. 1 ). During weeks 7-39 post-inoculation (p.i.) (3-35 weeks after the beginning of drug treatment) there were significantly fewer (P<0.05) virus isolations from PBMC of treated than of control lambs, with a mean of 41.1% and 66.1%, respectively. There was a continuing trend of decreased viraemia after 3 weeks of drug treatment. Thus, in 10 out of 14 bleedings during weeks 7 to 39 after inoculation, the percentage of positive samples was lower in the group treated with PMEA than in the untreated control group (Fig. 1 ). The number of virus-infected PBMC in the blood samples, as judged by inoculation of 10 6 and 10 5 cells into tissue culture plates, was highest during the first 6 weeks after inoculation, with 10 6 PBMC testing positive in 50-60% and 10 5 PBMC in 35-40% of all samples. The number decreased after the seventh week, particularly in the treated group where no virus was isolated from 10 6 PBMC during the last 6 weeks before euthanasia. In contrast, virus was isolated from 10 6 PBMC in 20% of the samples from the control group during this period.
Virus was isolated from the CSF of 90% of the lambs at 4 weeks p.i., indicating an active CNS infection. Virus was found mostly in cells but also in the supernatant fluid after centrifugation. At euthanasia, virus was isolated from the CSF cells from one treated lamb but not from control lambs.
Isolation of visna virus from organs collected at euthanasia
Virus was recovered from 60% of all explant cultures from organs of PMEA-treated lambs and from 71% of control lambs (Table 2 ). In contrast, virus was isolated from only 7% and 11.5% of organ extracts from the two groups. There was not a significant difference in frequency of virus isolations from organs of treated and control lambs, except possibly for the lungs.
Antibody response
All the control lambs had a significant increase in visna virus antibodies at 8 weeks p.i. as measured by ELISA, with titres of 1 : 1800 to 1 : 5400. Two of the treated lambs were still negative by ELISA at this time, but the mean titres of both groups were the same or about 1 : 4000. At 12 weeks all the treated lambs were positive and both groups had mean titres of 1 : 145 000. Similarly, all the control lambs had neutralizing antibodies at 18 weeks p.i. and the treated lambs at 26 weeks p.i. As shown in Fig. 2 , the neutralizing antibody response was markedly slower in treated than in control lambs.
PMEA sensitivity of virus isolates
Virus recovered at euthanasia from PBMC and organ extracts of PMEA-treated lambs were tested for PMEA sensitivity because of the possibility that drug-resistant virus strains had emerged. None of the isolates was less sensitive to the drug than the original strain used for inoculation, which had an EC 50 of 0.3 µg/ml.
Concentration of PMEA in serum and CSF
Serum drug levels were measured in two sheep at 1-4 h after s.c. injection of PMEA (Table 3 ). The plasma halflife of the drug was estimated as 109 min. A low level of PMEA (0.15-0.16 µg/ml) was found in the CSF of both animals at 3 h after injection but increased to 1.3 and 1.5 µg/ml, respectively, at 4 h, i.e. to 8-10% of the serum concentration at that time. PMEA was not detectable in the CSF at 1 h after injection. *Blood was collected from the jugular vein at weekly intervals, beginning 2 weeks after inoculation. †Blood was collected at intervals of 1 to 4 weeks for up to 33 weeks after inoculation. ‡The lambs were injected s.c. three times weekly with PMEA, 10 mg/kg for 6 months followed by 25 mg/kg for 2 months. §Mean±SD.
Figure 1. Frequency of virus isolations from PBMC of lambs inoculated with visna virus and bled at intervals
Group 1 was injected s.c. three times weekly with PMEA, 10 mg/kg for 6 months followed by 25 mg/kg for 2 months. The arrow indicates beginning of PMEA treatment. Group 2 is the untreated control. 
Cell counts in CSF
The number of cells in the CSF showed a distinct individual variation ( Table 4 ). The numbers were highest at 1 month p.i. (when drug treatment began), varying in the PMEA-treated lambs from 17 to 470 cells/µl with an average of 125 and 242 cells/µl in the groups euthanized at 3.5 and 9 months, respectively. In the untreated control lambs the numbers varied from 11 to 874 cells/µl with an average of 115 and 256 cells/µl (Table 4 ). This indicates that there was an active inflammation in the CNS of most of the lambs at the beginning of drug treatment. At 9 weeks p.i. (after 5 weeks of PMEA treatment) the cell numbers were generally lower and the average values were similar in the treated and untreated groups (data not shown). At euthanasia, 3-5 months and 9 months p.i., there was still a distinct individual variation but the average cell numbers were similar for the treated lambs and untreated control lambs.
Histopathology
The lesions in the brain consisted mainly of periventricular inflammation, meningitis and inflammatory infiltration of the choroid plexus. In cases with more severe lesions, i.e. grading more than 3.0, inflammatory foci were found in the cerebral white matter and in the most severe cases extensive confluent lesions with myelin breakdown were observed. The severity of lesions showed considerable variation both in the treated and in the untreated control lambs euthanized at different times p.i. (Table 4 ). Several lambs in both groups had either no or questionable lesions. There was a distinct difference between the average lesion grades of treated and untreated control lambs euthanized 3-5 months p.i., grades being 1.0 and 3.3, respectively. However, the significance of this difference is questionable since there were only three lambs in each group and one of the control lambs had a grade of 6, which is the highest on the scale used. There was not a significant difference between the average lesion grades in treated and untreated control lambs euthanized 9 months p.i. No specific pathological changes were found in the inner organs and no signs of toxic effect were found in liver or kidney of the PMEAtreated lambs.
Clinical signs and biochemical parameters
Definite signs of clinical visna were observed in untreated control lamb number 1988 with the most severe lesions. A few days before euthanasia it showed paresis and ataxia of the hind legs and was prostrate when euthanized. Other clinical signs were non-specific and caused by injury from spinal puncture or by bacterial pneumonia at the beginning of the experiment. The lambs did not show specific sideeffects from the PMEA treatment. Their haemoglobin values and differential blood cell counts were normal at the time of euthanasia. Their creatinin, urea and γ-glutamyltransferase (GGT) values were mostly within the normal range and comparable to the control group, whereas the aspartate aminotransferase (ASAT) level was slightly increased in three animals, one in the treated group and two in the control group. A definite toxic effect of PMEA on liver and kidney function was therefore not detected.
On the other hand, most of the PMEA-treated lambs did not thrive as well as the untreated controls. Thus, the average weight of the treated lambs euthanized 3-5 months p.i. was 9.5 kg at the beginning of the treatment and only 10.5 kg at euthanasia, whereas the corresponding values for the untreated controls were 13.3 kg and 20.3 kg. Similarly, the average weights of the treated lambs euthanized 9 months p.i. were 10.9 kg and 22.4 kg at the beginning and the end of treatment, whereas the corresponding values for the untreated controls were 12.1 kg and 31.3 kg, respectively.
Discussion
In an earlier experiment (Thormar et al., 1995) , PMEA was found to have a considerable prophylactic effect on visna virus infection in lambs, if treatment was started 1 h before i.c. inoculation. There was a pronounced inhibition of viral replication as judged by reduced frequency of virus isolation from PBMC during the treatment and from various organs at euthanasia. Inflammatory lesions in the brain were also markedly less severe compared to the untreated control group. This experiment demonstrated the feasibility of using visna virus in lambs as a unique animal model for in vivo testing of candidate anti-HIV drugs. Table 4 . Cell counts in CSF and CNS lesion grades in PMEA-treated and in untreated control lambs euthanized at 3-5 and 9 months p.i.
In the present study the therapeutic efficacy of PMEA in this animal model was tested by delaying the initiation of treatment until 4 weeks p.i., when severe inflammatory lesions are known to be present in the brains of lambs inoculated i.c. with this neurovirulent virus strain (Georgsson et al., 1989) . At 4 weeks p.i., when the PMEA treatment was started, most of the lambs had increased cell counts in the CSF and virus was isolated from the CSF of about 90% of the lambs, indicating that the infection was indeed in an active acute phase. Since in the previous study, three weekly doses of 10 mg/kg PMEA showed maximum efficacy it was decided to use this regimen. There was a marked reduction in the frequency of virus isolations from the PBMC of the treated group as compared to the control group during weeks 7-39 after inoculation (Fig. 1 ) and the total number of virus isolations during this period was significantly lower in the treated group (P<0.05) (Table 1) . From these results it can be concluded that PMEA treatment reduced the visna virus load in the blood during and after the acute phase of the infection. This conclusion is supported by the slower antibody response in the treated group. Increasing the dose to 25 mg/kg after week 30 did not seem to alter the efficacy of the treatment.
There was no difference in the frequency of virus isolation from explant cultures from organs of PMEA-treated and control groups. This could be expected because the infection was probably well established in the brain and other organs at the time drug treatment was begun. It has been shown that most visna virus-infected cells in the brain are not expressing the viral genome but become productive in explant cultures (Haase, 1986) . Such cells would obviously not be affected by drug treatment. Visna virus was rarely isolated from organ extracts ( Table 2) and only from two of seven PMEA-treated lambs and from three of eight controls. Because of the low number of isolations from extracts, it cannot be concluded whether or not the PMEA treatment inhibited virus replication in the brain or other organs. A histopathological study of tissue samples from various areas of the brain showed considerable variation in the severity of lesions in both treated and untreated lambs and the average lesion grades were similar. This indicates that the replication of virus in the brain was similar in both groups.
PMEA analysis showed significant concentrations of the drug in the CSF at 4 h after s.c. injection, indicating a delayed penetration into the CNS. The average PMEA concentration in the CSF of 1.4 µg/ml is about 10% of the plasma concentration at 4 h (Table 3) and almost fivefold higher than the EC 50 value of 0.3 µg/ml determined for visna virus in cell culture (Thormar et al., 1993) .
The present study has shown only a minimum therapeutic effect of PMEA on established visna virus infection in lambs and the results partly agree with a recent study on the therapeutic effect of PMEA in cats with chronic feline immunodeficiency virus infection, where no detectable reduction was found in the viral load in plasma after s.c. injection of 20 mg/kg PMEA three times weekly for 6 weeks (Vahlenkamp et al., 1995) . On the other hand, in a study of the efficacy of PMEA treatment in chronic simian immunodeficiency virus (SIV) infection in macaques, the drug caused a marked reduction in the number of viral isolations from PBMC when administered s.c. at a dose of 20 mg/kg daily for 4 to 8 weeks, which caused mild sideeffects in some cases (Tsai et al., 1995) . This is a considerably higher dose than used in the present study of visna virus. Even the high dose of PMEA used in the study on SIV infection did not affect the tissue distribution of the virus at various times after the end of drug treatment. In a more recent study on the effect of PMEA treatment in mice with murine AIDS, caused by murine leukaemia virus, the drug did not prevent disease progression even at a dose of 100 mg/kg three times weekly for 9 weeks (Y Suruga, M Makino, Y Okada, H Tanata, E de Clercq & M Baba, unpublished results). These results are in line with the present findings for visna virus infection.
In conclusion, this study has demonstrated that PMEA has only a minor therapeutic effect on established visna virus infection in lambs. Although visna virus infection can be used as an in vivo model for testing of anti-lentiviral drugs, a long-term experiment as performed here has certain drawbacks, one being the large weight of the lambs when they grow older. Much additional information is apparently not gained from long-term drug treatments as compared to shorter treatment periods of 8 to 12 weeks.
